









Emerging Roles of Perivascular Adipose Tissue in Regulation of Vascular Functions
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Abstract: Clinical and experimental studies provide increasing evidence that obesity is a major cardiovascular risk factor and that the 
adipose tissue is not just for regulation of lipid and energy homeostasis. Accordingly, the endocrine secretion of adipose tissue is impli-
cated in the pathogenesis of vascular diseases. Whilst the functions of visceral and subcutaneous adipose tissue are relatively well stud-
ied, the role of perivascular adipose tissue in regulation of vascular functions is usually ignored. Emerging evidence indicates that peri-
vascular adipose tissue is involved in the regulation of various physiological and pathological processes such as vascular smooth muscle 
contraction, vascular wall remodeling and inflammation, and, consequently, atherosclerosis and hypertension. Here we present an up-
dated overview of vascular adipobiology, focusing on perivascular adipose tissue. 
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INTRODUCTION 
 Despite of recent progress in vascular biology and medicine, 
atherosclerotic cardiovascular disease remains the leading cause of 
death world wide [1,2]. Numerous risk factors such as hypercholes-
terolemia, hypertension, smoking, aging, and type 2 diabetes melli-
tus (T2DM) play important roles in the pathogenesis of atheroscle-
rosis [3]. Among the risk factors, obesity has received much atten-
tion in recent years, because it is becoming a global public health 
problem of epidemic proportions [4,5]. Importantly, obesity is not 
only an independent cardiovascular disease risk factor [6,7], but 
also increases the potential of other risk factors clustered in the 
metabolic syndrome, such as hypertension, T2DM, dyslipidemia, 
and prothrombotic states, thus further facilitating the progression of 
atherosclerosis [5,8]. Although the link between obesity and car-
diovascular disease is well documented, the underlying pathophysi-
ological mechanisms remain elusive. Research in recent years pro-
vided compelling evidence suggesting that adipose tissue-secreted 
endocrine factors referred to as adipokines may indeed be an impor-
tant link between obesity and cardiovascular disease [reviewed in 
9].  
 Since the discovery of leptin in 1994 [10] adipose tissue is no 
longer considered as only an energy storage site. It is recognized as 
an important endocrine and paracrine organ producing a growing 
number of adipokines [11-13]. Adipokines are involved not only in 
the regulation of body weight and lipid metabolism, but also in 
insulin sensitivity, inflammation, thrombosis, and vascular endothe-
lial and smooth muscle cell functions. The unfavorable changes in 
production in adipokines under certain pathological conditions such 
as obesity and obesity-associated metabolic disorders may play 
important roles in pathogenesis of atherosclerosis.  
 Adipose tissue from different locations in the body may exhibit 
different biological functions [14]. Indeed, patients with visceral 
adiposity are at high risk of developing insulin resistance, dyslipi-
demia, atherothrombosis and hypertension, pinpointing the intra-
abdominal visceral adipose tissue as the major culprits in these 
disorders [15-20]. Perhaps, this is related to a greater capacity of 
visceral adipose tissue to synthesize and release pro-atherogenic 
adipokines, compared to subcutaneous adipose tissue [21]; these 
aspects have been reviewed [22,23] and will not be discussed here.  
 Here we present an updated overview of vascular adipobiology, 
focusing on perivascular adipose tissue (PVAT). Although the 
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interest in PVAT emerged only very recently [24], a couple of stud-
ies have provided supportive evidence that this tissue may play an 
important role in obesity-associated vascular disease by influencing 
smooth muscle cell (SMC) contraction, vascular structural remodel-
ing, and vascular inflammation.  
PVAT REGULATES VASCULAR CONTRACTION 
 Vascular contraction is primarily determined by the biological 
properties of medial SMC [25]. The function of vascular SMC is 
regulated by neuronal and hormonal mechanisms. In the past two 
decades much interest has been focused on the regulatory role of 
the inner layer of blood vessels, the endothelium, in regulation of 
vascular contraction [26]. Indeed, endothelial cells control vascular 
functions by releasing numerous factors that influence (i) SMC 
relaxation (e.g. nitric oxide, prostacyclin, endothelium-derived 
hyperpolarizing factor), (ii) SMC contraction (e.g. endothelin-1, 
thromboxane/endoperoxides), and (iii) SMC growth [27]. Conven-
tional wisdom hold that the outermost layer of blood vessels, the 
PVAT, is solely for structural support of blood vessels and its pos-
sible role in the regulation of vascular functions was largely ig-
nored. It was in 1991 when Soltis and Cassis [28] reported for the 
first time that PVAT can influence vascular contraction. These 
authors showed that the contractile responses to norepinephrine 
were significantly reduced in rat aortas with PVAT as compared to 
aortas in which PVAT was removed. No further research progress 
was made in this aspect of vascular biology during the following 10 
years, until Löhn et al. [29] demonstrated in 2002 that peri-aortic 
adipose tissue produces a relaxing factor, tentatively dubbed adi-
pose-derived relaxing factor (ADRF) [also see 30-32]. ADRF inhib-
its vascular contractions evoked by various vasoconstrictors such as 
serotonin, angiotensin II or phenylephrine [29]. The same group 
further revealed that the release of supposed relaxing factor(s) from 
perivascular fat surrounding rat aortas is dependent on Ca2+, pro-
tein tyrosine kinase, and protein kinase A [30]. The chemical nature 
of the relaxing factor(s) is largely unknown. It seems that it is a 
protein which causes vasorelaxation by opening ATP-dependent K+
(KATP) channels in SMC. A similar observation was also described 
in rat small mesenteric arteries [31]. In this vascular bed, the peri-
vascular fat inhibits vascular contraction through a relaxing fac-
tor(s) that also causes membrane hyperpolarisation via opening of a 
distinct type of K+ channels namely voltage-dependent K+ channels 
(Kv). These results suggest that PVAT at different vascular bed 
may release different relaxing factors (Fig. 1). The production of 
vascular relaxant hyperpolarizing factor(s) from PVAT has also 
been confirmed in human internal thoracic arteries [32]. The 
physiological relevance of this relaxing factor is not yet clear. Its 
function is well preserved in a genetic obesity animal model, 
Zucker diabetic fatty (ZDF) rats [29], which are deficient in func-
tional leptin receptors [33]. Whether there are adverse functional 
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changes in perivascular fat in other animal models of obesity or 
obesity-related metabolic disorders as well as in, for example, spon-
taneously hypertensive rats (SHR) and Watanabe hereditary hyper-
lipidemic rabbits, warrants further investigation. Interestingly, a 
recent study reports that the offspring of Wistar rats receiving nico-
tine during pregnancy and lactation had increased postnatal body 
weight and an increased amount of PVAT in the thoracic aorta and 
mesenteric arteries as compared to offspring of control dams [34]. 
Vasoconstrictions to phenylephrine in aortas of offspring from con-
trol dams are reduced by PVAT. Importantly, this effect is, how-
ever, absent in the offspring of nicotine-exposed dams [34]. The 
results implicate that prenatal smoking could increase adiposity and 
decrease the production of the perivascular fat-derived relaxing 
factor(s), which may play a role in vascular dysfunction in children 
exposed to cigarette smoke in utero or in subjects with cigarette 
smoking [34]. 
 Adipose tissue is an important source of pro-inflammatory cy-
tokines such as tumour necrosis factor-alpha (TNF-), interleukin-
1beta (IL-1), and IL-6, and the chemokines monocyte chemoat-
tractant protein-1 (MCP-1) and IL-8 [35] (Fig. 1). An increased 
production of these adipokines under obesity or obesity-associated 
diseases may be involved in vascular dyfunctions via interfering 
with insulin-mediated signaling pathways in endothelial cells as 
postulated recently by Yudkin and colleagues in their hypothesis of 
“vasocrine” signaling from perivascular fat (36). Insulin has been 
demonstrated to stimulate nitric oxide (NO) release via endothelial 
NO synthase (eNOS) causing vascular relaxation, and also influ-
ence endothelin-1 (ET-1) production in endothelial cells (37-41). 
Insulin-stimulated production of NO is mediated by insulin recep-
tor/IRS/PI3K/Akt/eNOS pathway [39, 42,43] and ET-1 production 
is mediated by ERKs pathway [41,44]. Under physiological condi-
tions the production of NO and ET-1 is balanced [40,45,46]. 
Through the release of endothelial NO, insulin may induce post-
prandial increase in blood flow in nutritive microcirculation favour-
ing glucose uptake in the insulin target organs. However, with con-
tinued calorie excess and/or physical inactivity, vasoregulatory 
periarteriolar fat accumulates. Secretion of TNF- from this peri-
vascular fat may reduce endothelial NO release by interfering with 
PI3K/Akt/eNOS pathway, resulting in reduced insulin-induced 
vasodilatation or even vasoconstriction exerted by preserved pro-
duction of ET-1 [44,47-49]. This imbalance of endothelium-derived 
vasoactive factors will reduce blood flow and substrate delivery to 
target organs, thereby, protects them from excess substrate delivery 
and further fat accumulation around vasculature. This may repre-
sent a sophisticated control mechanism to regulate postprandial 
substrate partition during conditions of calorie excess [36]. If this 
mechanism occurs in the vital organs such as heart, the epicardial 
adipose tissue, and particularly pericoronary adipose tissue, may 
enlarge and, consequently, such a protective mechanism might 
become harmful in cardiovascular biology.  
PVAT REGULATES VASCULAR REMODELING  
 Besides the regulatory role in vascular tone, PVAT may also be 
involved in regulation of structural remodeling of the vascular wall. 
Arterial remodeling is defined as any enduring change in the size 
and/or composition of an adult blood vessel that allows blood ves-
sels to adapt to the change in local blood flow pattern [50]. A nega-
tive remodeling underlines the pathogenesis of major cardiovascu-
lar diseases such as atherosclerosis, restenosis after vascular inter-
vention, hypertension, and also vascular aging [51-54]. It is already 
recognized that negative vascular remodeling is primarily mediated 
by adventitial myofibroblasts [55-57]. SMC migration/proliferation 
from media toward the lumen and/or myofibroblast migration from 
adventitia and subsequent secretion of extracellular matrix compo-
nents cause neointimal formation, a soil for atherosclerotic plaque 
growth [58]. Whether PVAT is also involved in vascular remodel-
ing is at present unclear. Several growth factors released from adi-
pose tissue cells and involved in the regulation of SMC prolifera-
tion and/or migration have been identified. Examples of SMC 
growth promoters include lysophosphatidic acid [59, 60], angio-
tensin II [61], TNF-, leptin, fibroblast growth factor, insulin-like 
growth factor, and heparin-binding epidermal growth factor-like 
growth factor [62-64], whereas adiponectin is a SMC growth inhibi-
tor [65] (Fig. 1). Adiponectin is the most abundant adipocyte-
secreted factor identified until now, and is the best characterized 
adipokine involved in vascular structural changes. Adiponectin 
increases insulin sensitivity, and its production is negatively associ-
ated with obesity, T2DM and coronary artery disease [66-71]. Adi-
ponectin-deficient mice reveal pronounced insulin resistance and 
atherosclerosis and also greater neointimal proliferation after bal-
loon injury than wild-type animals [72,73]. Whether perivascular 
adipocytes have the same functions in production of growth pro-
moters and inhibitors as the adipocytes in other depots remains 
elusive. 
Fig. (1). Scheme illustrating the role of perivascular adipose tissue (PVAT) 
in the regulation of vascular functions. Under normal conditions (lower 
panel), PVAT produces adipose-derived relaxing factors (ADRF) and cell 
growth inhibitors, which prevent vasoconstriction and smooth muscle cell 
proliferation, respectively. Under the conditions of obesity and aging (upper 
panel), perivascular adipose depot enlarges and produces more inflamma-
tory adipokines and growth factors, which damage endothelial cells and 
stimulate smooth muscle cell proliferation, resulting in vascular wall thick-
ening and lumen narrowing. EC, endothelial cells; SMC, smooth muscle 
cells. 
 Our most recent study provided the first evidence suggesting 
that PVAT influences vascular SMC proliferation [74]. We demon-
strated that differentiated but not undifferentiated adipocytes in 
culture stimulate SMC proliferation, which is in line with the find-
ing by Manabe et al. [75] showing that mature primary adipocytes, 
but not preadipocytes, isolated from subcutaneous adipose tissue of 
Wistar rats stimulate breast cancer cell proliferation. We further 
demonstrated that PVAT also releases growth factor(s) stimulating 
SMC proliferation. The growth promoting effect of peri-aortic adi-
pose tissue is significantly enhanced in aged rats (24 months) as 
compared to young rats (3 months), suggesting that it might be 
involved in age-associated vascular intimal thickening or negative 
vascular remodelling (Fig. 1). Furthermore, the SMC growth pro-











induced obese WKY rats (Figure), but not in the genetically obese 
Zucker fa/fa rats, which are deficient in functional leptin receptors. 
The contrasting results between the two obesity models might be 
due to the lack of effects of leptin in the obese Zucker fa/fa rats. 
Indeed, leptin presence positively correlates with cardiovascular 
risk [76,77]. The obese Zucker fa/fa rats are relatively resistant to 
atherosclerosis and changes in vascular functions [78-80]. Also, the 
production of the newly suggested relaxing factor(s) released from 
peri-aortic adipose tissue in Zucker fa/fa rats remains preserved as 
demonstrated recently [29].  
 The chemical nature of the SMC growth factor(s) released from 
mature adipocytes and PVAT has not yet been fully identified. Our 
experiments suggest that it is at least a heat- and trypsin-resistant 
hydrosoluble protein growth factor(s) with a molecular weight >100 
kD, which stimulates SMC proliferation synergistically with other 
growth promoters released from adipocytes or PVAT. It remains for 
future studies to identify the individual components released by 
PVAT and to investigate their functional roles in vascular remodel-
ing under physiological and pathological conditions.  
PVAT REGULATES VASCULAR INFLAMMATION 
 Obesity is associated with chronic low-grade inflammation, 
which has been shown to be a major pathogen of atherosclerosis 
[1]. Plasma concentrations of the pro- inflammatory mediators IL-6, 
TNF-, plasminogen activator inhibitor-1, and C-reactive protein 
(CRP) are elevated in obese patients [81-87]. Recent studies sug-
gest that inflammation-related adipokines may contribute to the 
development and progression of atherosclerosis [9,24,71]. The role 
of PVAT in vascular inflammation is emerging (Fig. 1). It has been 
shown that inflammatory cells such as neutrophils and macrophages 
accumulated in the PVAT after vascular injury [88], and in human 
atherosclerosis, macrophages and T cells [89] and mast cells 
[90,91] are located in PVAT, thus contributing to vascular inflam-
matory response in atherosclerosis. This hypothesis is supported by 
the experiments showing that conditioned medium from PVAT of 
human aortas is able to stimulate migration of white blood cells, 
mostly mediated by the adipose-secreted chemokines MCP-1/CCL2 
(CCL, cysteine-cysteine motif chemokine ligand) and IL-8/CXCL8 
[89]. The hypothesis of a putative local role of PVAT in athero-
genesis has been supported by recent studies demonstrating higher 
levels of pro-inflammatory factors such as IL-1ß, MCP-1, TNF-,
and resistin but lower levels of adiponectin expression in epicardial 
than subcutaneous adipose tissue [92,93]. Since abdominal adipos-
ity is an independent predictor of cardiovascular risk [94], these 
observations may reinforce the hypothesis that adipose tissue-
accumulated inflammatory cells [88-90,95-97] may play an impor-
tant role in obesity-related atherosclerosis. One important lesson 
that could be learned from the recent PVAT studies is that we 
should no longer remove it from the artery wall, but keep it attached 
and in place, and subject to thorough examinations, as recently 
postulated [24]. 
CONCLUSIONS 
 We reviewed recent evidence implicating the regulatory role of 
PVAT in vascular biology, focusing on PVAT-derived adipokines 
and vascular tone, SMC proliferation, and vascular inflammation. 
Yet, many lessons remain to be learned from PVAT and its 
paracrine contribution to vascular physiology and pathology. Ac-
cordingly, new experimental approaches which can specifically 
modify PVAT functions (e.g. PVAT-depleted mice and ADRF-
deficient mice) without altering those of adipose tissues at other 
locations should be developed in future studies of vascular 
adipobiology.  
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